[1]

Gomez-Casal R, Bhattacharya C, Ganesh N, et al. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes[J/OL]. Mol Cancer, 2013, 12(1):94[2017-02-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751356/pdf/1476-4598-12-94.pdf.DOI:10.1186/1476-4598-12-94.
[2] 李景涛, 邓垒, 张文珏, 等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志, 2016, 40(2):100-105. DOI:10.3760/cma.j.issn.1673-4114. 2016.02. 003.
Li JT, Deng L, Zhang WJ, et al. Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J]. Int J Radiat Med Nucl Med, 2016, 40(2):100-105.  doi: 10.3760/cma.j.issn.1673-4114.2016.02.003
[3] Ma W, Ma CN, Li XD, et al. Examining the effect of gene reduction in miR-95 and enhanced radiosensitivity in non-small cell lung cancer[J]. Cancer Gene Ther, 2016, 23(2/3):66-71. DOI:10.1038/cgt.2016.2.
[4] Torres-Roca JF, Stevens CW. Predicting response to clinical radiotherapy:past, present, and future directions[J]. Cancer Control, 2008, 15(2):151-156.
[5] Chapoval AI, Ni J, Lau JS, et al. B7-H3:a costimulatory molecule for T cell activation and IFN-gamma production[J]. Nat Immunol, 2001, 2(3):269-274. DOI:10.1038/85339.
[6] Ling V, Wu PW, Spaulding V, et al. Duplication of Primate and rodent B7-H3 immunoglobulin V-and C-like domains:divergent history of functional redundancy and exon loss[J]. Genomics, 2003, 82(3):365-377. DOI:10.1016/S0888-7543(03)00126-5.
[7] Prasad DV, Nguyen T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells[J]. J Immunol, 2004, 173(4):2500-2506. DOI:10.4049/jimmunol.173.4.2500.
[8] Sun M, Richards S, Prasad DV, et al. Characterization of mouse and human B7-H3 genes[J]. J Immunol, 2002, 168(12):6294-6297. DOI:10.4049/jimmunol.168.12.6294.
[9] Yamato I, Sho M, Nomi T, et al. Clinical importance of B7-H3 expression in human pancreatic cancer[J]. Br J Cancer, 2009, 101(10):1709-1716. DOI:10.1038/sj.bjc.6605375.
[10] Roth TJ, Sheinin Y, Lohse CM, et al. B7-H3 ligand expression by prostate cancer:A novel marker of prognosis and potential target for therapy[J]. Cancer Res, 2007, 67(16):7893-7900. DOI:10.1158/0008-5472.CAN-07-1068.
[11] Zang X, Thompson RH, Al-Ahmadie HA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome[J]. Proc Natl Acad Sci U S A, 2007, 104(49):19458-19463. DOI:10.1073/pnas.0709802104.
[12] Crispen PL, Sheinin Y, Roth TJ, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma[J]. Clin Cancer Res, 2008, 14(16):5150-5157. DOI:10.1158/1078-0432.CCR-08-0536.
[13]

Qin XJ, Zhang HL, Ye DW, et al. B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma[J/OL]. Onco Targets Ther, 2013, 6:1667-1673[2017-02-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833620/pdf/ott-6-1667.pdf.DOI:10.2147/OTT.S53565.
[14] Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer[J]. Lung Cancer, 2006, 53(2):143-151. DOI:10.1016/j.lungcan.2006.05.012.
[15] Schneider T, Hoffmann H, Dienemann H, et al. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3[J]. J Thorac Oncol, 2011, 6(7):1162-1168. DOI:10.1097/JTO.0b013e31821c-421d.
[16] Boland JM, Kwon ED, Harrington SM, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung[J]. Clin Lung Cancer, 2013, 14(2):157-163. DOI:10.1016/j.cllc.2012.05. 006.
[17]

Jin YJ, Zhang P, Li J, et al. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer[J/OL]. Int J Clin Exp Pathol, 2015, 8(11):13987-13995[2017-02-01]. http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4713496&blobtype=pdf.
[18] Ding J, Miao ZH, Meng LH, et al. Emerging cancer therapeutic opportunities target DNA-repair systems[J]. Trends Pharmacol Sci, 2006, 27(6):338-344. DOI:10.1016/j.tips.2006.04.007.
[19] Kaliberov SA, Kaliberova LN, Yari H, et al. Retargeted adenoviruses for radiation-guided gene delivery[J]. Cancer Gene Ther, 2016, 23(9):303-314. DOI:10.1038/cgt.2016.32.
[20] Lehmann BD, Paine MS, Brooks AM, et al. Senescence-associated exosome release from human prostate cancer cells[J]. Cancer Res. 2008, 68(19):7864-7871. DOI:10.1158/0008-5472.CAN-07-6538.